glp-1 therapy for diabetes Receptor Agonists as Treatments Type 2 A clinician's perspective 📝 GLP-1

The study showed CagriSema achieved a 23% reduction in body weight over 84 weeks, compared to 25.5% for Eli Lilly's tirzepatide in the trial

doi: 10.1016/S0140-6736(21)01324-6 71 FrasJPDaviesMJRosenstockJPrez ManghiFCFernndez LandLBergmanBKet al

If you have any questions in the meantime, don't hesitate to reach out

Tirzepatide raised the bar to ~20%

GLP-3 RT (RETATRUTIDE) Description: GLP-3 RT (Retatrutide) is an investigational unimolecular triple agonist of the glucagon-like peptide-1 receptor (GLP-1R), glucose-dependent insulinotropic polypeptide receptor (GIPR), and glucagon receptor (GCGR)

However, changing behaviors is notoriously challenging, requiring ongoing support, motivation, and personalized guidance